Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16168637 | 0.77 | GAA (0.47) | GAAL3MBTL1 | |
| SCHEMBL12846026 | 0.77 | GAA (0.47) | GAAL3MBTL1 | |
| SCHEMBL20464751 | 0.77 | GAA (0.47) | GAAL3MBTL1 | |
| SCHEMBL22380762 | 0.75 | GAA (0.45) | GAAL3MBTL1 | |
| SCHEMBL1818885 | 0.75 | GAA (0.45) | GAAL3MBTL1 | |
| SCHEMBL12846374 | 0.75 | GAA (0.45) | GAAL3MBTL1 | |
| SCHEMBL2875979 | 0.71 | GAA (0.44) | GAAL3MBTL1 | |
| SCHEMBL4439487 | 0.71 | GAA (0.41) | GAAL3MBTL1 | |
| SCHEMBL16161304 | 0.71 | GAA (0.41) | GAAL3MBTL1 | |
| SCHEMBL18545636 | 0.71 | GAA (0.41) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017031239-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-23 | — | — | WO | disclosed |
| US-8466130-B2 | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers | COLBY PHARMACEUTICAL COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | COLBY PHARMACEUTICAL COMPANY (US) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | TFAM, HSPD1, NLN | GAA 1476/4885L3MBTL1 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.